Kandi Technologies (NASDAQ:KNDI) is often described as a go-kart manufacturer. Actually, the Jinhua-based company develops and manufactures electrically-powered specialty vehicles, including: all-terrain vehicles, utility vehicles, three-wheeled motorcycles, mini-cars, as well as go-karts. On Monday, KNDIs share price skyrocketed 23.33 percent to $21.41 after the company reported fourth-quarter earnings. Kandis revenue soared 92 percent to $50.6 million, with $40 million of the companys revenue resulting from a 193.7 percent increase in its sale of electric vehicles. KNDI sold 3,568 electric vehicles during the fourth quarter. On a year-over-year basis, KNDIs profits jumped 259 percent to $4.6 million compared with $1.3 million during the fourth quarter of 2012. Better yet, many investors are anticipating that the company will benefit from Chinese government incentives for electric vehicle manufacturers with expanding efforts to fight the nations air pollution problem. Mondays other star from China was Sky-mobi (NASDAQ:MOBI) a Hangzhou-based provider of mobile software applications. MOBI shares soared 12.42 percent to $11.13 on Monday, after the company announced a partnership between its subsidiary, Mopin Technology and China Unicoms Wo Store. The press release issued by Sky-mobi focused on the idea that customers will be able to receive some degree of tech support at the Wo Store: Michael Tao Song, Chairman and Chief Executive Officer of Sky-mobi stated, We have been arduously working on this project since 2010 when we found through customer feedback that customers visiting the operators physical stores expected more than just assistance with choosing and purchasing a new phone.
Up 560%, hot momentum stock?
And five other biotechs rallied anywhere from 34% to 90% following their offerings.” Jorg Greuel | Digital Vision | Getty Images The next IPO that Cramer thinks could follow the pattern outlined above hits markets this week. It’s MediWound, which is expected to price on Thurs., March 20, between $14 and $16.” “This is an Israeli biotech firm,” Cramer said. “It makes a drug called NexoBrid that could transform the way in which burn victims are treated.” As groundbreaking as this and other potential new drugs may be, “the company doesn’t expect to turn a profit until 2018, when NexoBrid comes up for FDA approvalthat’s a long way off,” Cramer said. Therefore, “I’m recommending this as a trade off of the IPO, not necessarily as a longer-term investment.” “I bet it will give you a nice pop on its first day of trading. I think the stock could quickly trade up to around $22,” Cramer said.
Then, “The second leg of the rally came in November, when investors learned that the company had gone into business with Apple .” Investors bought the stock on speculation that Apple might switch from Corning-made glass for its iPhone touchscreens to more durable sapphire products made by GTAT. Although that kind of announcement would likely drive a further advance, “We can’t be sure that Apple’s going to make this move,” Cramer said. Therefore, Cramer sees this stock as a spec play only. “If you like this story, I say wait for the next market-wide sell off; then you have my permission to buy GTAT, but only for speculation.” ———————————————————- SunEdison In the past year, shares of SunEdison have gained a whopping 350%. “Until last June, this hottest stock today company was known as MEMC and traded under the symbol WFR,” Cramer said.
Could this stock surge on the IPO?
The stock closed at Rs116.68 with a gain of Rs3.05 on trade turnover of 7.25 million shares. An analyst said that investors accumulated shares on the expectation for good earnings. Pakistan State Oil also remained the hot stock among traders at the KSE on Tuesday. The stock closed at Rs422.64 with a gain of Rs5.33 on trade turnover of 2.20 million shares.
Hot Stocks: Geron Corporation (NASDAQ:GERN), Synovus Financial Corp. (NYSE:SNV), Staples, Inc. (NASDAQ:SPLS), IsoRay, Inc. (NYSEMKT:ISR)
Why Should Investors Buy SPLS After the Recent Fall? Just Go Here and Find Out IsoRay, Inc. ( NYSEMKT:ISR ), declared that IASIS Medical has received formal approval for the sale of IsoRays complete product line in Greece. ISR is a clinical technology company and modernizer in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic cancer. IsoRay, Inc.